PubMed Health⌕ Search

Biomedical subjects

Marya Strand

Publications and source records attributed to Marya Strand.

3 recordsLinked to original sources

Promoting the uptake and use of evidence: an overview of the problem.

Application of evidence-based practice principles in neonatology requires that the use of proved therapies is monitored and evaluated. Although studies of neonatal center practice variation are appearing in the literature, careful, population-based assessments of the use of proved therapies are lacking. Few center comparison studies focus on proved therapies or explore the patient-independent reasons for practice variation. For a specific proved neonatal therapy, the ideal studies would carefully determine the number of eligible patients and the proportion who receive the therapy and then evaluate the characteristics of hospitals, clinicians, parents, and other decision makers among users and non-users. This information may allow for targeted interventions to disseminate evidence to both clinicians and parents, train clinicians critically to appraise the evidence, address identified barriers, and train clinicians to recognize and deal with the inevitable uncertainties associated with changing practice. The authors suggest that studies designed to evaluate the net benefit of proposed new therapies include a plan for evaluating the extent of incorporation of the therapy into practice if and when the therapy is shown to be beneficial. Studies should also rigorously evaluate alternative methods of disseminating the primary study's findings and identify the characteristics of clinicians, patients, and parents associated with practice change.

Diffusion of Innovation↗

The multiple negative randomized controlled trials in perinatology--why?

Many of the multicenter trials in perinatal medicine have been negative in that they have shown no benefit for the intervention relative to the control. Although a negative trial can improve patient care by the avoidance of an unnecessary treatment, most trials are designed with the intent of the intervention improving outcomes. We selectively reviewed a number of recent trials in order to identify why the trials were negative. In general, the preliminary information on which the trials were based, which was a small trial or a meta-analysis of multiple small trials, was not robust or predictive. The weak preliminary information together with limited numbers of patients, problematic primary outcomes and a poor understanding of the biology of neonatal diseases has limited the ability to reliably design trials with positive outcomes.

Humans↗

Effects of high PCO2 on ventilated preterm lamb lungs.

High PCO(2) levels attenuate reperfusion injury and ventilation-induced injury in isolated and perfused lungs. We asked whether premature lambs could tolerate 6 h of ventilation with a PCO(2) >80 mm Hg and whether the high PCO(2) modulated the ventilator-induced injury. Preterm surfactant-treated lambs were ventilated for 30 min with a high tidal volume (V(T)) to induce lung injury. The lambs then were ventilated for 5.5 h with a V(T) of 6-9 mL/kg to achieve a PCO(2) of 40-50 mm Hg in the control group. CO(2) was added to the ventilator circuit of a high PCO(2) group to maintain an average PCO(2) of 95 +/- 5 mm Hg. The high PCO(2) lambs had heart rates, blood pressures, plasma cortisol values, and oxygenation equivalent to the control lambs. The lungs of the high PCO(2) group had significantly higher gas volumes and had less lung injury by histopathology. Indicators of inflammation (white blood cells, hydrogen peroxide production, and IL-1beta and IL-8 cytokine mRNA expression in cells from the alveolar wash) qualitatively indicated less injury in the high PCO(2) group, although the differences were not significant. Preterm lambs tolerated a very high PCO(2) without physiologic compromise for 6 h. The high PCO(2) may attenuate ventilator-induced lung injury in the preterm.

Animals↗